HTB

Antiretrovirals

Lenacapavir in MDR HIV: phase 3 results of CAPELLA study published

CROI 2022: Dolutegravir plus recycled tenofovir rather than switch to AZT: public health approach to second-line ART

FDA approves dispersible dolutegravir/abacavir/3TC for children

Access to ibalizumab uncertain in Europe: TaiMed looking for new partner after Thera quits

CROI 2022: Islatravir studies for HIV treatment and PrEP

US FDA removes need for oral lead-in with long-acting cabotegravir/rilpivirine injections: indication expanded to adolescents

CROI 2022: Biktarvy (B/F/TAF): 5-year follow-up in two phase 3 studies

CROI 2022: Injectable CAB/RPV-LA results after three years follow-up

CROI 2022: Lenacapavir: 54 week results in treatment-naive participants of CALIBRATE study

CROI 2022: Lenacapavir in treatment-experienced participants, and as PrEP in macaques

US FDA approves 2-monthly dosing option for long-acting injectable cabotegravir/rilpivirine

Gilead to pay $1.25 billion plus royalties to ViiV Healthcare for bictegravir infringing on dolutegravir patent

Selected islatravir studies stop enrolment: further complications with important investigational drugs

FDA further limit use of islatravir in ongoing studies

Lenacapavir: drug resistance after viral rebound in treatment experienced participants

Implications of historical M184V on use of dual dolutegravir/lamivudine ART

Stopping long-acting cabotegravir/rilpivirine: 1 in 5 trial participants didn’t restart oral ART within eight weeks

Islatravir plus doravirine dual ART: 144 week follow-up from phase 2 study

NICE approves long-acting cabotegravir and rilpivirine injections in England and Wales

MSD/Merck stop once-weekly NNRTI MK-8507: islatravir studies continue with closer monitoring

NHS Scotland approves long-acting cabotegravir and rilpivirine injections

Lenacapavir submitted to EMA for MDR HIV

Pipeline report 2021: HIV drugs in development

IAS 2021: lenacapavir studies show impressive results in naive, extensive drug resistance and potential as PrEP

IAS 2021: HIV pipeline drugs: CAB/RPV LA, fostemsavir, paediatric dolutegravir, lenacapavir, islatravir, MK-8507 and albuvirtide

Lenacapavir submitted to FDA as long-acting treatment for MDR HIV

Featured CROI 2021: First results using capsid inhibitor lenacapavir against MDR HIV: potential for six-monthly ART and PrEP

Gilead and Merck/MSD to collaborate on long-acting HIV combination of lenacapavir and islatravir

CROI 2021: Once-daily GSK254 maturation inhibitor as treatment for HIV multidrug resistance

CROI 2021: Dosing for once-weekly oral ART: islatravir plus MK-8507 studies due to start in 2021

US FDA approves long-acting injectable HIV treatment: monthly dosing

Long-acting injectable HIV treatment approved in the EU: includes two-monthly dosing

Fostemsavir approved in the EU (Rukobia): NICE deferred in the UK

EU approves dolutegravir 5 mg dispersible for children older than four weeks

New formulation of dolutegravir will make modern ART available for babies and young children at less than $120 a year

New neonatal liquid formulations of dolutegravir have comparable bioavailability to dispersible paediatric tablet

EMA issues positive opinion to approve cabotegravir LA/rilpivirine LA injections (Vocabria/Rekambys) as new HIV treatment

Capsid inhibitor lenacapavir, dosed six-monthly, has high barrier to drug resistance and no cross-resistance to other classes

Single doses of MK-8507 reduce viral load by mean –1.5 log and support once-weekly dosing above 80 mg

Capsid inhibitor lenacapavir (GS-6207) allows for 6-monthly dosing

US FDA approves dolutegravir/lamivudine (Dovato) as switch option

EMA extends indication for darunavir/r to include adolescents >12 years

ViiV resubmits cabotegravir plus rilpivirine long-acting injections (Cabenuva, Vocabria) to FDA for approval

ADVANCE 96-week results: dolutegravir weight gain continues, especially in women and when used with TAF – no evidence of a plateau

FDA approves fostemsavir (Rukobia) for multidrug resistant HIV in the US

FDA approves dolutegravir formulations to treat infants and young children

Fit for purpose: antiretroviral treatment optimisation March 2020

Long-acting cabotegravir and rilpivirine injections support two-monthly dosing

Safety and PK of bNAb elipovimab (GS-9722) support two-weekly dosing

First results with long-acting capsid inhibitor GS-6207: oral and subcutaneous formulations for use in naïve and multidrug resistance

Long-acting cabotegravir and rilpivirine: similar results in women and men 

FDA decision on long-acting cabotegravir/rilpivirine (Cabenuva, Vocabria) injections delayed due to scale-up manufacturing problems

Fostemsavir submitted to EMA for treating multidrug resistant HIV

Gilead announces licensing agreement for Rockefeller University bNAbs

Capsid inhibitor GS-6207 (lenacapavir): potential for 6 monthly dosing for MDR HIV

Dolutegravir/lamivudine as dual ART

Weight changes with doravirine-based first line therapy

Doravirine approved by NHS England as single NNRTI and as part of FDC with 3TC/TDF

Fostemsavir submitted to US FDA for multidrug resistant HIV

Paediatric dispersible formulation of dolutegravir submitted to EMA and FDA

Ibalizumab approved in the EU

HIV suppression and safety with ibalizumab at 48 weeks in expanded access

Oral cabotegravir and rilpivirine is durable for 5.5 years in LATTE study

Dolutegravir plus rilpivirine had good virologic, safety record in clinics before single tablet available

Switching from TDF to TAF linked to higher BMI and cardio risk

Post navigation